Compare AbbVie Inc (ABBV) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.53. The key difference: AbbVie Inc pays a 2.72% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | GPTY | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $261.07 | $50.52 |
52-Week Low | $184.85 | $34.73 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
GPTY trades at $44.83, up 3.15% in the last 24 hours, with technical indicators showing a bearish trend but oversold RSI signals. The ETF maintains a consistent weekly dividend payout strategy, with recent distributions ranging from $0.30 to $0.38. News highlights focus on its AI and tech portfolio exposure and option-income strategy, though technical momentum remains weak.
Outlook is mixed: high dividend yield and AI theme appeal to income investors, but bearish technicals and reliance on semiconductor momentum pose risks. Investor sentiment is cautious amid volatile tech sector performance, requiring close monitoring of NAV stability and market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
